This webinar will reveal how experts approach current therapeutic decisions for their patients with ß-thalassemia and provide a look ahead at new data and promising agents that may change practice in the near future. Renowned ß-thalassemia experts will discuss the available evidence for both transfusion-dependent thalassemia (TDT) and non-TDT, including patient case presentations, their treatment recommendations for each case, and reflection on challenges that affect therapeutic decisions. Recent clinical trial evidence and ongoing clinical trials on novel therapeutic approaches, including erythroid maturation agents and gene therapy with lentiviral vectors, will be presented and discussed, with a focus how these agents may affect management strategies for patients with ß-thalassemia in the near future. Throughout the webinar, attendees will interact with the experts through interactive case-based challenges and polling questions. Finally, attendees will be able to submit questions directly to the panel for their consideration. Discussion topics include:

• The Medical Need for Novel Therapies for ß-Thalassemia
• Optimizing Current Management of ß-Thalassemia
• Evolving Role of Biologic Therapies for ß-Thalassemia
• The Promise of Gene Therapy in ß-Thalassemia